Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying age, diagnosis of alcohol dependence, and understanding of the trial. Written consent is required.

For women with childbearing potential and men with partners who can become pregnant, a highly effective birth control method must be used until one month after the last administration of the investigational medication. A negative pregnancy test is required at enrollment.

The baseline visit occurs on day -2. During this visit, initial measurements of alcohol craving are taken using the Obsessive Compulsive Drinking Scale (OCDS-G).

Additional assessments may include quality of life, depressive symptoms, and anxiety levels.

On day 1, treatment begins. Participants receive either cannabidiol capsules or placebo capsules in addition to a standard treatment of 50mg oral naltrexone.

The dosage of cannabidiol is either 800mg or 1200mg, taken orally. The specific dosage and whether it is cannabidiol or placebo is determined randomly.

Follow-up visits are scheduled on days 7, 14, 28, 42, 105, and 196. During these visits, alcohol craving and other health indicators are assessed.

On day 14, the end of treatment is marked, and primary outcomes are measured. Secondary outcomes are assessed at subsequent visits.

Participants may agree to additional assessments, such as using a study-specific app to track alcohol consumption and craving weekly.

For some participants, additional tests like brain imaging may be conducted to study brain activity related to alcohol cues.